Betrixaban

Generic Name
Betrixaban
Brand Names
BEVYXXA
Drug Type
Small Molecule
Chemical Formula
C23H22ClN5O3
CAS Number
330942-05-7
Unique Ingredient Identifier
74RWP7W0J9
Background

Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboe...

Indication

Betrixaban is indicated for prophylaxis of venous thromboembolism (VTE) in conditions of moderate to severe restricted mobility or in patients that qualify as in risk of VTE.

Associated Conditions
Venous Thromboembolism
Associated Therapies
-
Clinical Trials
Related News

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: Betrixaban
First Posted Date
2018-01-12
Last Posted Date
2023-02-21
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
32
Registration Number
NCT03397888
Locations
🇺🇸

Clinical Pharmacology of Miami, Hialeah, Florida, United States

Study Evaluating Betrixaban in Pediatric Participants

Phase 1
Terminated
Conditions
VTE Prophylaxis
Interventions
Drug: Betrixaban
First Posted Date
2017-11-17
Last Posted Date
2024-01-12
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
21
Registration Number
NCT03346083
Locations
🇺🇸

Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States

🇷🇺

Children's City Clinical Hospital, Moscow, Russian Federation

🇷🇺

Pirogov Russian National Research Medical University, Moscow, Russian Federation

and more 17 locations

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Betrixaban
First Posted Date
2015-11-04
Last Posted Date
2023-08-08
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
52
Registration Number
NCT02596100

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Betrixaban
First Posted Date
2013-01-10
Last Posted Date
2023-08-08
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
8
Registration Number
NCT01765868

Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

First Posted Date
2012-04-23
Last Posted Date
2023-08-07
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
7513
Registration Number
NCT01583218

A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment

Phase 1
Completed
Conditions
Renal Impairment
Interventions
Drug: Betrixaban
First Posted Date
2009-10-21
Last Posted Date
2023-08-22
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
32
Registration Number
NCT00999336
Locations
🇩🇪

APEX GmbH, Munich, Germany

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Phase 2
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: betrixaban
Drug: Warfarin
First Posted Date
2008-08-28
Last Posted Date
2023-08-07
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
508
Registration Number
NCT00742859
Locations
🇨🇦

Portola Investigational Site, Montreal, Quebec, Canada

Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)

Phase 2
Completed
Conditions
Thromboembolism
Interventions
Drug: Betrixaban
Drug: Enoxaparin
First Posted Date
2006-09-13
Last Posted Date
2023-08-07
Lead Sponsor
Portola Pharmaceuticals
Target Recruit Count
215
Registration Number
NCT00375609
Locations
🇨🇦

Montreal General Hospital, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy